# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Diagnostics Assessment Programme**

# Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer

Stakeholder list

## Companies

Agendia N.V. Exact Sciences UK, Ltd Myriad International GmbH Veracyte Inc

#### **Professional groups**

Association of Breast Surgery Royal College of Physicians The Royal College of Pathologists

#### Patient/carer groups

Breast Cancer Now

#### Research groups

Peony Breast Care Unit Newcastle upon Tyne Hospital NHS Trust UCL (University College London) Cancer Institute

#### A provider of NHS services

University Hospitals Coventry and Warwickshire NHS Trust

#### External Assessment Group

School of Health and Related Research

#### Others

Department of Health Healthcare Improvement Scotland Illumina Medicines and Healthcare products Regulatory Agency NHS England NHS England Genomics Unit Welsh Government

# **Definitions:**

# **Stakeholders**

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, companies, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

# External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technologies.